Literature DB >> 28603778

DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

William C Reinhold1, Anish Thomas1,2, Yves Pommier1.   

Abstract

In the current drive to incorporate molecular markers into treatment-selection for precision medicine, there has been a significant and we believe ill-advised omission of the large and routinely used group of drugs whose mechanism of action is DNA damage.

Entities:  

Keywords:  DNA-damaging agents; Precision medicine

Mesh：

Substances：

Year:  2017        PMID： 28603778      PMCID： PMC5461960          DOI： 10.1016/j.trecan.2016.11.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  10 in total

Review 1.  Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Authors:  William C Reinhold; Margot Sunshine; Sudhir Varma; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-06-05       Impact factor: 12.531

2.  Tumor necrosis factor-mediated cytotoxicity involves ADP-ribosylation.

Authors:  S Agarwal; B E Drysdale; H S Shin
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

3.  Temozolomide: mechanisms of action, repair and resistance.

Authors:  Jihong Zhang; Malcolm F G Stevens; Tracey D Bradshaw
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 4.  Targeting the DNA Damage Response in Cancer.

Authors:  Mark J O'Connor
Journal:  Mol Cell       Date:  2015-11-19       Impact factor: 17.970

5.  Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.

Authors:  Fabricio G Sousa; Renata Matuo; Sai-Wen Tang; Vinodh N Rajapakse; Augustin Luna; Chris Sander; Sudhir Varma; Paul H G Simon; James H Doroshow; William C Reinhold; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2015-02-11

Review 6.  Omics Profiling in Precision Oncology.

Authors:  Kun-Hsing Yu; Michael Snyder
Journal:  Mol Cell Proteomics       Date:  2016-04-20       Impact factor: 5.911

Review 7.  An overview of the design and conduct of the BATTLE trials.

Authors:  Suyu Liu; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2015-09

8.  Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.

Authors:  Gabriele Zoppoli; Marie Regairaz; Elisabetta Leo; William C Reinhold; Sudhir Varma; Alberto Ballestrero; James H Doroshow; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

9.  Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Authors:  Neil Johnson; Shawn F Johnson; Wei Yao; Yu-Chen Li; Young-Eun Choi; Andrea J Bernhardy; Yifan Wang; Marzia Capelletti; Kristopher A Sarosiek; Lisa A Moreau; Dipanjan Chowdhury; Anneka Wickramanayake; Maria I Harrell; Joyce F Liu; Alan D D'Andrea; Alexander Miron; Elizabeth M Swisher; Geoffrey I Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-01       Impact factor: 11.205

10.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action.

Authors:  Matthew G Rees; Brinton Seashore-Ludlow; Jaime H Cheah; Drew J Adams; Edmund V Price; Shubhroz Gill; Sarah Javaid; Matthew E Coletti; Victor L Jones; Nicole E Bodycombe; Christian K Soule; Benjamin Alexander; Ava Li; Philip Montgomery; Joanne D Kotz; C Suk-Yee Hon; Benito Munoz; Ted Liefeld; Vlado Dančík; Daniel A Haber; Clary B Clish; Joshua A Bittker; Michelle Palmer; Bridget K Wagner; Paul A Clemons; Alykhan F Shamji; Stuart L Schreiber
Journal:  Nat Chem Biol       Date:  2015-12-14       Impact factor: 15.040
  10 in total
  9 in total

Review 1.  Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Authors:  Junko Murai; Anish Thomas; Markku Miettinen; Yves Pommier
Journal:  Pharmacol Ther       Date:  2019-05-23       Impact factor: 12.310

Review 2.  Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?

Authors:  Marketa Bednarikova; Jitka Hausnerova; Lucie Ehrlichova; Kvetoslava Matulova; Eliska Gazarkova; Lubos Minar; Vit Weinberger
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

3.  Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Authors:  Sai-Wen Tang; Anish Thomas; Junko Murai; Jane B Trepel; Susan E Bates; Vinodh N Rajapakse; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

4.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

Review 5.  Precision Oncology: The Road Ahead.

Authors:  Daniela Senft; Mark D M Leiserson; Eytan Ruppin; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2017-09-05       Impact factor: 11.951

6.  Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

Authors:  Junko Murai; Hongliang Zhang; Lorinc Pongor; Sai-Wen Tang; Ukhyun Jo; Fumiya Moribe; Yixiao Ma; Masaru Tomita; Yves Pommier
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

7.  An "olivomycin A" derivative from a sponge-associated Streptomyces sp. strain SP 85.

Authors:  Mohsen Gozari; Nima Bahador; Mohammad Seddiq Mortazavi; Ebrahim Eftekhar; Amir Reza Jassbi
Journal:  3 Biotech       Date:  2019-11-07       Impact factor: 2.406

8.  Candidate biomarker assessment for pharmacological response.

Authors:  William C Reinhold; Fathi Elloumi; Sudhir Varma; Jacques Robert; Gordon B Mills; Yves Pommier
Journal:  Transl Oncol       Date:  2020-07-08       Impact factor: 4.243

9.  SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.

Authors:  Ukhyun Jo; Yasuhisa Murai; Sirisha Chakka; Lu Chen; Ken Cheng; Junko Murai; Liton Kumar Saha; Lisa M Miller Jenkins; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.